GlassBox
Niihara International, Inc. Offering Circular Dated: January 31, 2026
Millions of patients worldwide lack access to affordable therapies for sickle cell disease. Niihara International is advancing a generic prescription-grade L‑glutamine oral powder (Entabor2) designed to reduce acute complications of sickle cell disease—at a cost structure intended to support broad access in underserved markets. With regulatory pathways underway and manufacturing assets in place, we are positioned to scale globally. Now we invite you to participate.
Niihara International, Inc. Offering Circular Dated: January 31, 2026
Get in for
$2/Share
Millions of Patients with Sickle Cell Disease
Sickle cell disease affects tens of millions of patients globally, with particularly high prevalence across India, Africa, and the Middle East, where access to affordable therapies remains limited.
Advanced gene‑based therapies are prohibitively expensive and require sophisticated medical infrastructure, placing them out of reach for most patients in developing regions.
Many regions face delays in regulatory approvals, fragmented supply chains, and dependence on single‑source manufacturers, constraining consistent access to treatment.
Millions of Patients
Regulatory
Supply Chain Barriers
Millions of Patients with Sickle Cell Disease
Sickle cell disease affects tens of millions of patients globally, with particularly high prevalence across India, Africa, and the Middle East, where access to affordable therapies remains limited.
Advanced gene‑based therapies are prohibitively expensive and require sophisticated medical infrastructure, placing them out of reach for most patients in developing regions.
Many regions face delays in regulatory approvals, fragmented supply chains, and dependence on single‑source manufacturers, constraining consistent access to treatment.
Potential Ban
on Fracking
300%+
Decline in
New Capital Investment
Intensifying Regulation
of Abandoned
Sites
.
Current climate has made
some low-producing wells uneconomical to operate or even shut down Many producers don’t have
in-house servicing or capital to pay an outside servicer to decommission Historically limited
government enforcement Legal shell game has
allowed for non-producing wells to be aggregated in SPVsNiihara International is focused on commercializing Entabor2, a generic L‑glutamine oral powder that is pharmaceutically equivalent to previously FDA‑approved L‑glutamine therapies.
Our competitive advantage is driven by:
• Prior FDA precedent for L‑glutamine in sickle cell treatment
• Ownership of a pharmaceutical manufacturing facility in Japan capable of producing pharmaceutical‑grade L‑glutamine
• A cost structure designed to support large‑scale distribution in emerging markets
• Established regulatory engagement in the U.S., India, and Oman By retrofitting our existing facility and securing regulatory approvals, we aim to control supply, reduce costs, and improve access to essential therapy.
Prescription Grade Generic Therapy vs. High Cost Branded or Experimental Treatments
Established Manufacturing Asset vs. Capital Intensive New Build Facilities
Targeted Emerging Market Distribution vs. Limited Global Availability
Niihara International is committed to expanding access to essential sickle cell therapies in regions with the greatest unmet need. Access our offering portal and become an investor today.
Estimated sickle cell patients in India alone
Targeted gross margin following commercialization
Targeted timeline to revenue generation following offering close
Get in for $2.00/Share
Expanding access to an established therapy through lower cost generic production.
Initial focus on India
Africa
$2.00
Share
(Get in for $2.00/Share)
This offering is designed to fund regulatory approvals, manufacturing upgrades, supply chain development, and initial commercialization of Entabor2 across key global markets. By investing today, you are participating in the expansion of a proven therapy to millions of patients who currently lack access.
INVEST IN NIIHARA INTERNATIONALGet in for $2/Share
Get in for $1/Share
Access our offering portal and become an investor today!
We are poised to capitalize on billions of dollars in government spending on the plugging and reclamation of abandoned oil wells over the coming decade.
We are well positioned to apply new technology
which we have been beta testing for the last several years
A seasoned pharmaceutical executive and founder with deep experience in sickle cell therapeutics, regulatory strategy, and global commercialization. Dr. Niihara previously led FDA-approved L-glutamine development and has personally raised over $2 million to advance Niihara International's mission.
[email protected]
(310) 430-9496
24 Covered Wagon Ln. Rolling Hills Estates, California, 90274The Company is a commercial-stage biopharmaceutical company primarily focused on the development, commercialization, and distribution of innovative therapies for rare and orphan diseases. The company’s lead product is an FDA-approved prescription-grade L-glutamine oral powder designed to reduce acute complications associated with sickle cell disease (SCD) in patients aged five years and older. The Company markets and distributes it’s lead product in the United States and select international markets, including the Middle East and North Africa (MENA) region. Additionally, the company has pursued regulatory approvals in India and other emerging markets.